Investigation of clinical effects of treatment with fine particle inhaled corticosteroids exhalation through the nose

Investigation of clinical effects of treatment with fine particle inhaled corticosteroids exhalation through the nose - Clinical effects of treatment with ICS exhalation through the nose

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018038

Enrollment

Registered

2015-07-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic chronic rhinosinusitis with bronchial asthma

Interventions

fine particle inhaled corticosteroids exhalation through the nose: HFA-BDP (800 microgram per day) for 4 weeks fine particle inhaled placebo exhalation through the nose: practice inhaler (8 doses per

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with eosinophilic chronic rhinosinusitis with asthma who are scheduled for endoscopic sinus surgery

Exclusion criteria

Exclusion criteria: 1. exacerbation within 4 weeks (eg. infection and asthma attack) 2. concomitant disease currently treated (eg. heart diseases, hematologic disorders, respiratory diseases) 3. pregnant patients 4. possibility of lack of examination security.

Design outcomes

Primary

Measure	Time frame
SInus CT findings before and after treatment	—

Countries

Japan

Contacts

Public ContactChikako Yasuoka

Kansai Medical University Research Devision

kenkyu@hirakata.kmu.ac.jp072-804-2291

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026